跳转至内容
Merck
所有图片(1)

Key Documents

View All Documentation

06863

Sigma-Aldrich

甘氨酰去氧胆酸

≥96.0% (TLC)

别名:

N-(3α,7β-二羟基-5β-cholan-24-oyl）甘氨酸, N-[(3α, 5β, 7β）-3,7-二羟基-24-氧代胆甾烷-24-基 ] 甘氨酸, GUDCA, 乌索脱氧胆基甘氨酸, 甘氨酰脱氧胆酸

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C26H43NO5
CAS号:
64480-66-6
分子量:
449.62
MDL號碼:
MFCD00137427
分類程式碼代碼:
12161900
PubChem物質ID:
329748294
NACRES:
NA.25

生物源

synthetic

品質等級

100

化驗

≥96.0% (TLC)

形狀

powder

官能基

carboxylic acid

SMILES 字串

[H][C@@]12[C@]([C@](CC[C@@H](O)C3)(C)[C@]3([H])C[C@@H]2O)([H])CC[C@@]4(C)[C@@]1([H])CC[C@]4([H])[C@]([H])(C)CCC(NCC(O)=O)=O

InChI

1S/C26H43NO5/c1-15(4-7-22(30)27-14-23(31)32)18-5-6-19-24-20(9-11-26(18,19)3)25(2)10-8-17(28)12-16(25)13-21(24)29/h15-21,24,28-29H,4-14H2,1-3H3,(H,27,30)(H,31,32)/t15-,16+,17-,18-,19+,20+,21+,24+,25+,26-/m1/s1

InChI 密鑰

GHCZAUBVMUEKKP-XROMFQGDSA-N

相关类别

應用


  • Glycoursodeoxycholic Acid Alleviates Arterial Thrombosis via Suppressing Diacylglycerol Kinases Activity in Platelet.: Highlights the therapeutic potential of Glycoursodeoxycholic acid in alleviating arterial thrombosis by inhibiting diacylglycerol kinase activity in platelets (Yang et al., 2024).

生化／生理作用

来源于酰基甘氨酸的次级胆汁酸。据报道甘氨脱氧胆酸 (GUDCA) 具有细胞保护和抗炎作用。

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

Slide 1 of 3

1 of 3

β-Muricholic Acid ≥98% (HPLC)

Sigma-Aldrich

SML2372

β-Muricholic Acid

猪胆酸 Avanti Research™ - A Croda Brand

Avanti

700159P

猪胆酸

石胆酸 ≥95%

Sigma-Aldrich

L6250

石胆酸

A Roda et al.
The Journal of biological chemistry, 258(10), 6362-6370 (1983-05-25)
The relationship between chemical structure and the concentration at which self-association occurs in water or in 0.15 M Na+ ion was examined for more than 50 bile salts and bile salt analogues varying in substituents on the steroid nucleus or
A Roda et al.
Pharmaceutical research, 11(5), 642-647 (1994-05-01)
A new enteric-coated formulation of sodium ursodeoxycholate was prepared and administered to man. The barrier film disintegrates and releases the drug only at pH > or = 5.5. The sodium salt of glycoursodeoxycholate was also prepared and encapsulated like ursodeoxycholate.
Ewa Ellis et al.
Hepatology (Baltimore, Md.), 38(4), 930-938 (2003-09-27)
Primary human hepatocytes were used to elucidate the effect of individual bile acids on bile acid formation in human liver. Hepatocytes were treated with free as well as glycine-conjugated bile acids. Bile acid formation and messenger RNA (mRNA) levels of
Kazuya Maeda et al.
Molecular pharmaceutics, 3(1), 70-77 (2006-05-12)
Ursodeoxycholate (UDCA) is widely used for the treatment of cholestatic liver disease. After oral administration, UDCA is absorbed, taken up efficiently by hepatocytes, and conjugated mainly with glycine to form glycoursodeoxycholate (GUDC) or partly with taurine to form tauroursodeoxycholate (TUDC)
Sandra L Silva et al.
Neuropharmacology, 62(7), 2398-2408 (2012-03-01)
Neuronal oxidative damage and cell death by unconjugated bilirubin (UCB) showed to be mediated by overstimulation of glutamate receptors and nitric oxide (NO) production, which was abrogated by the bile acid glycoursodeoxycholic acid (GUDCA). Microglia, a crucial mediator of CNS
查看所有相关文献

实验方案

HPLC Separation of Bile Acids with Ascentis Express C18

Investigate bile acid roles in gut hormone profiles and glycemic control, vital for clinical labs exploring potential mechanisms.

相关内容

Bile Acids Kit for LC-MS

Bile Acids (BA) are synthesized in the liver and play important roles in cholesterol homeostasis, absorption of vitamins and lipids, and various key metabolic processes.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门